US Patent

US10039757 — C-Met modulator pharmaceutical compositions

Method of Use · Assigned to Exelixis Inc · Expires 2031-07-18 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions and unit dosage forms containing Compound I, a C-Met modulator.

USPTO Abstract

Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1480`	—	cabozantinib-s-malate
`U-1480`	—	cabozantinib-s-malate
`U-1480`	—	cabozantinib-s-malate

Patent Metadata

Patent number: US10039757
Jurisdiction: US
Classification: Method of Use
Expires: 2031-07-18
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.